Regular ArticleDominant-Negative Mutation of p53 Tumor Suppressor Gene in Endometrial Carcinoma
References (30)
- et al.
p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes
Gynecol Oncol
(1996) - et al.
p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis
Hum Pathol
(1995) - et al.
Establishment of a cell line of human endometrial adenocarcinoma in vitro
Am J Obstet Gynecol
(1972) - et al.
Establishment of human endometrial adenocarcinoma cell line containing estradiol-17β and progesterone receptors
Gynecol Oncol
(1984) - et al.
Establishment and characterization of human cell lines from a serous papillary adenocarcinoma of the endometrium
Gynecol Oncol
(1994) - et al.
Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion
Gynecol Oncol
(1994) - et al.
Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma
Acta Obstet Gynecol Scand
(2000) - et al.
Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers
J Natl Cancer Inst
(2000) - et al.
Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium
Cancer Res
(1992) - et al.
The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways
Cancer
(2000)
Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence
Cancer
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer
EMBO J
Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis
Cancer Res
A simple p53 functional assay for screening cell lines, blood, and tumors
Proc Natl Acad Sci USA
Cited by (23)
Novel TP53 gene mutation and correlation with p53 immunohistochemistry in a mixed epithelial carcinoma of the endometrium
2013, Gynecologic Oncology ReportsCitation Excerpt :We hypothesize that the second mutation, R306* (c.916C > T), further altered the p53 protein product, leading to increased intracytosolic protein accumulation, and therefore stronger reactivity by immunohistochemistry. Although there is a single reported case of pure serous carcinoma of the endometrium with the R273H (c.818 G > A) mutation in exon 8 of the TP53 gene (Sakuragi et al., 2001), this is the first case to describe the R306* (c.916C > T) mutation in this setting, and the only case thus far documenting two concomitant TP53 gene mutations in a single endometrial tumor. Our findings raise the possibility that type I and type II tumors may be more closely related than previously thought, as evidenced by a common TP53 gene mutation arising in histologically distinct areas of the same tumor.
P53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer
2012, Gynecologic OncologyCitation Excerpt :Western blot is a method, which can be used in clinical practice to evaluate p53 expression. Most authors used immunohistochemistry [13] or PCR [24] for evaluating p53 alterations in endometrial cancer. As in immunohistochemistry, a regular p53 expression in Western blot does not necessarily exclude p53 mutation [25].
Bax, Bcl-2, and p53 expression in endometrial cancer
2002, Gynecologic OncologyType-II endometrial cancer: role of adipokines
2019, Archives of Gynecology and ObstetricsExpression of p53, Bcl-2 and Bax in endometrial carcinoma, endometrial hyperplasia and normal endometrium: a histopathological study
2018, Journal of Obstetrics and Gynaecology
- 1
To whom correspondence and reprint requests should be addressed at Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, N-15, W-7, Kitaku, Sapporo 060-8638, Japan. Fax: +81-11-706-7711. E-mail: [email protected].